Hans T. Scambye joins Sunstone as Venture Partner

Hans T. Scambye joins Sunstone as Venture Partner Sunstone is delighted to announce that experienced biotech executive and CEO of Galecto Hans T. Schambye will be joining our team as new Venture Partner as of 1st February 2025. With a background as an MD and PhD Hans...

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk

Fund IV company Cardior Pharmaceuticals acquired by Novo Nordisk Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. The company’s therapeutic approach targets distinctive...